ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases

ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA immunotherapies NV (“eTheRNA”), a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its ground-breaking TriMix technology, have agreed to collaborate on the development of vaccine candidates for infectious diseases. It is anticipated that by combining ConserV’s and eTheRNA’s technologies, the new vaccines will induce potent immune responses to protect against highly mutagenic viruses.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...